Mallinckrodt's medical sales grow 4%
This article was originally published in Clinica
Executive Summary
Mallinckrodt Medical's revenues were up 4% to $1,055 million in the 12 months to the end of June. Major contributors to sales growth were anaesthetic and nuclear medicine products augmented by the January 1996 acquisition of Liebel-Flarsheim, a manufacturer of contrast media injection systems.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.